160 related articles for article (PubMed ID: 11825917)
1. Androgen receptor expression in ductal carcinoma in situ of the breast: relation to oestrogen and progesterone receptors.
Selim AG; El-Ayat G; Wells CA
J Clin Pathol; 2002 Jan; 55(1):14-6. PubMed ID: 11825917
[TBL] [Abstract][Full Text] [Related]
2. Oestrogen receptor negativity as a marker for high-grade ductal carcinoma in situ of the breast.
Baqai T; Shousha S
Histopathology; 2003 May; 42(5):440-7. PubMed ID: 12713620
[TBL] [Abstract][Full Text] [Related]
3. Expression of androgen receptor and two androgen-induced proteins (apolipoprotein D and pepsinogen C) in ductal carcinoma in situ of the breast.
Gonzalez LO; Corte MD; Junquera S; Bongera M; Rodriguez JC; Vizoso FJ
Histopathology; 2007 Jun; 50(7):866-74. PubMed ID: 17543076
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical categorisation of ductal carcinoma in situ of the breast.
Meijnen P; Peterse JL; Antonini N; Rutgers EJ; van de Vijver MJ
Br J Cancer; 2008 Jan; 98(1):137-42. PubMed ID: 18043578
[TBL] [Abstract][Full Text] [Related]
5. Loss of bcl-2 expression in ductal carcinoma in situ of the breast relates to poor histological differentiation and to expression of p53 and c-erbB-2 proteins.
Quinn CM; Ostrowski JL; Harkins L; Rice AJ; Loney DP
Histopathology; 1998 Dec; 33(6):531-6. PubMed ID: 9870147
[TBL] [Abstract][Full Text] [Related]
6. Immunohistochemical localization of gross cystic disease fluid protein-15, -24 and -44 in ductal carcinoma in situ of the breast: relationship to the degree of differentiation.
Selim AA; El-Ayat G; Wells CA
Histopathology; 2001 Aug; 39(2):198-202. PubMed ID: 11493337
[TBL] [Abstract][Full Text] [Related]
7. Apocrine carcinoma as triple-negative breast cancer: novel definition of apocrine-type carcinoma as estrogen/progesterone receptor-negative and androgen receptor-positive invasive ductal carcinoma.
Tsutsumi Y
Jpn J Clin Oncol; 2012 May; 42(5):375-86. PubMed ID: 22450930
[TBL] [Abstract][Full Text] [Related]
8. Ductal carcinoma in situ of the breast. Histologic categorization and its relationship to ploidy and immunohistochemical expression of hormone receptors, p53, and c-erbB-2 protein.
Leal CB; Schmitt FC; Bento MJ; Maia NC; Lopes CS
Cancer; 1995 Apr; 75(8):2123-31. PubMed ID: 7697603
[TBL] [Abstract][Full Text] [Related]
9. Does Progesterone Receptor Matter in the Risk of Recurrence for Patients With Ductal Carcinoma in Situ?
Chaudhary LN; Jawa Z; Hanif A; Szabo A; Kamaraju S; Cheng YC; Chitambar CR
WMJ; 2018 Jun; 117(2):62-67. PubMed ID: 30048574
[TBL] [Abstract][Full Text] [Related]
10. Clonal alteration of breast cancer receptors between primary ductal carcinoma in situ (DCIS) and corresponding local events.
Karlsson E; Sandelin K; Appelgren J; Zhou W; Jirström K; Bergh J; Wärnberg F
Eur J Cancer; 2014 Feb; 50(3):517-24. PubMed ID: 24275214
[TBL] [Abstract][Full Text] [Related]
11. Expression of HER2neu in ductal carcinoma in situ is associated with local recurrence.
Han K; Nofech-Mozes S; Narod S; Hanna W; Vesprini D; Saskin R; Taylor C; Kong I; Paszat L; Rakovitch E
Clin Oncol (R Coll Radiol); 2012 Apr; 24(3):183-9. PubMed ID: 21958729
[TBL] [Abstract][Full Text] [Related]
12. Androgen receptor expression in a Sri Lankan patient cohort with early breast carcinoma.
Wijesinghe HD; Wijesinghe GK; Mansoor Z; Vigneshwara S; Fernando J; Gunasekera D; Lokuhetty MDS
BMC Womens Health; 2020 Sep; 20(1):206. PubMed ID: 32928183
[TBL] [Abstract][Full Text] [Related]
13. Androgen receptor expression in ductal carcinoma in situ of the breast: not a helpful marker for classification such as estrogen receptor alpha and progesterone receptor.
Rody A; Diallo R; Poremba C; Wuelfing P; Kissler S; Solbach C; Kaufmann M; Jackisch C
Appl Immunohistochem Mol Morphol; 2005 Mar; 13(1):25-9. PubMed ID: 15722790
[TBL] [Abstract][Full Text] [Related]
14. Cyclin D1 and associated proteins in mammary ductal carcinoma in situ and atypical ductal hyperplasia.
Gillett CE; Lee AH; Millis RR; Barnes DM
J Pathol; 1998 Apr; 184(4):396-400. PubMed ID: 9664905
[TBL] [Abstract][Full Text] [Related]
15. AgNOR analysis of atypical ductal hyperplasia and intraductal carcinoma of the breast.
Guski H; Hufnagl P; Kaufmann O; Krause M; Winzer KJ
Anal Quant Cytol Histol; 2000 Jun; 22(3):206-12. PubMed ID: 10872036
[TBL] [Abstract][Full Text] [Related]
16. Expression of androgen receptor in breast cancer and its significance as a prognostic factor.
Yu Q; Niu Y; Liu N; Zhang JZ; Liu TJ; Zhang RJ; Wang SL; Ding XM; Xiao XQ
Ann Oncol; 2011 Jun; 22(6):1288-1294. PubMed ID: 21109569
[TBL] [Abstract][Full Text] [Related]
17. Expression of Her2/neu, steroid receptors (ER and PR), Ki67 and p53 in invasive mammary ductal carcinoma associated with ductal carcinoma In Situ (DCIS) Versus invasive breast cancer alone.
Mylonas I; Makovitzky J; Jeschke U; Briese V; Friese K; Gerber B
Anticancer Res; 2005; 25(3A):1719-23. PubMed ID: 16033090
[TBL] [Abstract][Full Text] [Related]
18. [Expression of androgen receptor in breast carcinoma and its relationship with estrogen receptor, progesterone receptor and HER2 status].
Chen J; Zhang X; Tian R; Liu Y; Dong HM; Guo RF; Liang HY
Zhonghua Bing Li Xue Za Zhi; 2010 Nov; 39(11):743-6. PubMed ID: 21215164
[TBL] [Abstract][Full Text] [Related]
19. Differential Gene Expression in Ductal Carcinoma In Situ of the Breast Based on ERBB2 Status.
Agosto-Arroyo E; Isayeva T; Wei S; Almeida JS; Harada S
Cancer Control; 2017 Jan; 24(1):102-110. PubMed ID: 28178722
[TBL] [Abstract][Full Text] [Related]
20. Histological category and expression of hormone receptors in ductal carcinoma in situ of the breast.
Lebrecht A; Buchmann J; Hefler L; Lampe D; Koelbl H
Anticancer Res; 2002; 22(3):1909-11. PubMed ID: 12168892
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]